报告题目：From Microorganisms: Drug Delivery, Nanotechnology and Cancer Therapy
报 告 人：Dr. Xiuling Lu
Assistant Professor of Pharmaceutics
Department of Pharmaceutical Sciences
University of Connecticut
Some anti-cancer drugs derived from microorganisms are potent but very toxic. Site-specific drug delivery is critical. Nanotechnology-based cancer therapy has exhibited clear benefits including reduced patient side effects, improved circulatory retention and greater tumor targeting efficiency. The talk will focus on multifunctional nanoparticles carrying therapeutic agents for safer and more effective cancer treatment.
Xiuling Lu, Ph.D., an Assistant Professor of Pharmaceutics at the University of Connecticut, received her Ph.D. in Biochemical Engineering from the Chinese Academy of Sciences in 2005. She came to the USA in 2006 at the University of Kentucky as a Postdoctoral Scholar and received a prestige Benedict Cassen Post-Doctoral Fellowship Award from the Education and Research Foundation for the Society of Nuclear Medicine to work on dual imaging-therapeutic nanovectors in 2008. She has continued this line of research as a Research Assistant Professor at the University of North Carolina at Chapel Hill from 2008 to 2011, and then joined UConn School of Pharmacy in August, 2011. Dr.Lu’s research interests include nanoparticle-based drug delivery for improving therapeutic indices of anti-cancer agents, image-guided drug delivery for optimizing cancer diagnosis and therapy, and neutron-activatable nanoparticles for radiation therapy. Dr. Lu has more than 40 publications and 7 patent applications.